Dallah Healthcare Reports SAR 538.27M Net Profit in 2025
DALLAH HEALTH 4004.SA | 0.00 |
On 2026-03-04 15:52:31 (Saudi Time), Dallah Healthcare Co. announced its Annual financial results for the twelve months ended on December 31, 2025.
| Element List | Current Year | Previous Year | %Change | ||
|---|---|---|---|---|---|
| Sales/Revenue | 4,066.89 | 3,205.73 | 26.86 | ||
| Gross Profit (Loss) | 1,452.34 | 1,206.84 | 20.34 | ||
| Operational Profit (Loss) | 645.42 | 567.12 | 13.81 | ||
| Net Profit (Loss) Attributable to Shareholders of the Issuer | 538.27 | 471.2 | 14.23 | ||
| Total Comprehensive Income Attributable to Shareholders of the Issuer | 533.57 | 471.79 | 13.09 | ||
| Total Shareholders Equity (after Deducting Minority Equity) | 4,082.39 | 3,468.56 | 17.7 | ||
| Profit (Loss) per Share | 5.32 | 4.83 | |||
| All figures are in (Millions) Saudi Arabia, Riyals | |||||
| Element List | Amount | Percentage of the capital (%) | |
|---|---|---|---|
| Profit (Losses) Resulting From The Change In Investment Propertie’s Fair Value | - | - | |
| All figures are in (Millions) Saudi Arabia, Riyals | |||
| Element List | Explanation |
|---|---|
| The reason of the increase (decrease) in the sales/ revenues during the current year compared to the last year |
The Company achieved the highest annual and quarterly revenues in its history, along with approximately one million additional patient visits during 2025. Revenues for 2025 increased by 26.9% to reach SR 4,067m, compared to SR 3,206m in the previous year, representing an increase of SR 861m.
The revenue growth was driven by increasing quarterly revenues for the third consecutive quarter. Revenues for Q4 2025 reached SR 1,110m, marking the highest quarterly revenues ever achieved by the Company. This reflects an increase of 37.3% (SR 302m) compared to the Q4 2024, and an increase of 4.6% (SR 49m) compared to the preceding quarter.
Revenue growth was also supported by an unprecedented increase in patient visits across the Group, particularly following the completion of the acquisitions of Dallah Al Khobar Hospital and Dallah Al Ahsa Hospital, in addition to the continued expansion of the Group’s other facilities. The total number of patient visits in 2025 reached approximately 3.8 million, compared to 2.8 million in 2024, representing an increase of approximately one million visits, or 35.7%. The acquisition of Dallah Al Khobar Hospital and Dallah Al Ahsa Hospital increased the Group’s capacity by 37% through the addition of 424 beds (274 beds at Dallah Al Ahsa Hospital and 150 operational beds at Dallah Al Khobar Hospital). This percentage is expected to increase to 65% upon the full operation of Dallah Al Khobar Hospital with a capacity of 475 beds, bringing the Group’s total capacity to more than 1,900 beds.
Total revenues generated by the two hospitals from the acquisition date on 23 March 2025 until 31 December 2025 amounted to approximately SR 572m, representing 66.4% of the total increase in the Group’s revenues. This exceeded prior revenue projections for the two hospitals, which were estimated at approximately SR 500m, by SR 72m, representing an outperformance of 14.4% versus expectations.
The twoacquired hospitals recorded a significant revenue increase in 2025, particularly after operating under the umbrella of Dallah Healthcare Company. Their revenues increased by approximately SR 210m, representing a growth rate of 44.7% compared to 2024 (noting that the hospitals’ revenues in the prior year were not included in Dallah Healthcare’s revenues as they preceded the acquisition date).
As for the Group’s existing medical facilities prior to the acquisition, they also achieved revenue growth during the current year compared to the previous year, with a revenue increase of SR 289m, representing 33.6% of the total revenue increase of the Group and a growth rate of 8.3%. |
| The reason of the increase (decrease) in the net profit during the current year compared to the last year is |
Net profit attributed to shareholders for 2025 increased by 14.2% to reach SR 538m, compared to SR 471m in the previous year, representing an increase of SR 67m. This resulted in an increase in earnings per share (EPS) for the current year to SR 5.32 per share, compared to SR 4.83 per share in the previous year. This improvement is attributable to the following:
The increase in 2025 revenues led to a 20.3% rise in gross profit, reaching SR 1,452m compared to SR 1,207m in the previous year, an increase of SR 246m. Operating profit for 2025 also improved by 13.8% to reach SR 645m, compared to SR 567m in the previous year, an increase of SR 78m.
The increase in the Company’s share of results from associates amounted to approximately SR 9m.
In Q1 2025, the Company recognized gains of SR 51m from land contributed as an in-kind contribution to a real estate fund. In Q2 2025, the Company finalized the assessment years of its Zakat file up to 2023, resulting in the reversal of provisions amounting to SR 12.5m. In Q3 2025, following the acquisition of Dallah Al Khobar Hospital Company, the Company successfully renegotiated the terms of a long-term Murabaha financing facility and reduced the Murabaha cost, resulting in a remeasurement gain of SR 29.5m.
Regarding the performance of Dallah Al Khobar Hospital, leveraging Dallah Healthcare’s expertise in the healthcare sector, the Company significantly reduced the hospital’s losses following the acquisition. The hospital’s net loss for the year decreased by SR 127m, equivalent to a 72.2% reduction compared to 2024 (excluding the positive impact of the aforementioned loan remeasurement gain). The hospital also turned to profitability in Q4 2025, recording a net profit of SR 5m, compared to a net loss of SR 34m in the corresponding quarter of 2024. Accordingly, quarterly losses decreased by SR 39m, representing an improvement of 115%. The sharp turnaround in Dallah Al Khobar Hospital’s performance is attributable to substantial growth in patient visits and improved operational efficiency, noting that the hospital remains in its early stages of operation. (It should be noted that Dallah Al Khobar Hospital’s losses for 2024 were not included in Dallah Healthcare’s results as they preceded the acquisition date.)
The increase in net profit for 2025 was achieved despite the Company recording, in Q4 2025, white land fees related to the years 2023, 2024, and 2025 at Care Shield Company amounting to SR 12m. In addition, provisions and adjustments for perishable inventory and penalties were recorded at Dallah Pharma amounting to SR 17m.
Furthermore, net profit before financing costs, depreciation, amortization, and Zakat for the year increased by 22.8% to reach SR 922m, compared to SR 751m in the previous year, representing an increase of SR 171m. |
| Statement of the type of external auditor's report | Unmodified opinion |
| Comment mentioned in the external auditor’s report, mentioned in any of the following paragraphs (other matter, conservation, notice, disclaimer of opinion, or adverse opinion) | N/A |
| Reclassification of Comparison Items | Some comparative figures have been reclassified to better align with the classifications of the current year |
| Additional Information | - |
| Attached Documents |
|
Year-on-Year Performance Drivers
Sales increased 26.86% YoY to SAR 4,066.89 million, driven primarily by the acquisitions of Dallah Al Khobar Hospital and Dallah Al Ahsa Hospital in March 2025, which contributed SAR 572 million in revenues and added 424 beds to the Group's capacity. The revenue growth was further supported by approximately one million additional patient visits across the Group, reaching 3.8 million total visits compared to 2.8 million in 2024. Net profit attributable to shareholders rose 14.23% to SAR 538.27 million, benefiting from higher revenues that increased gross profit by 20.34%, one-time gains totaling SAR 92.5 million from land contributions and Zakat provision reversals, and a significant turnaround at Dallah Al Khobar Hospital which reduced its losses by 72.2% following operational improvements.
Other Items
The external auditors issued an unmodified opinion with no additional comments, disclaimers, or adverse remarks noted. The company reported record-breaking financial performance with revenues reaching SAR 4,066.89 million and net profit of SAR 538.27 million, representing increases of 26.86% and 14.23% respectively. Earnings per share improved to SAR 5.32 from SAR 4.83 in the previous year. Total shareholders' equity grew 17.7% to SAR 4,082.39 million. The financial statements included reclassifications of comparative figures to align with current year classifications, and no material uncertainties or significant risks were disclosed in the auditor's report.
Original announcement:
https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details/?anId=93455&anCat=1&cs=4004&locale=arAttached PDF document link:
https://www.saudiexchange.sa/Resources/fsPdf/21212_435_2026-03-04_15-32-55_en.pdfImportant Notice: The announcement information and market data in this report are sourced directly from the Saudi Exchange (Tadawul). This summary is generated by Sahm’s proprietary AI model for informational purposes only. While we strive for accuracy, it should not be construed as financial advice or an investment recommendation.